Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Arbor Biotechnologies logo — Genetic medicines for genetic diseases

Arbor Biotechnologies

Genetic medicines for genetic diseases

Founded 2016 United States Cambridge, United States 101 employees Total: $304.50M Biopharma, Biotechnology +1

General Information

Company Name Arbor Biotechnologies
Founded Year 2016
Location United States Cambridge, United States
Founders / Decision Makers
Team member
Employees 101
Industries Biopharma, Biotechnology, Life Sciences
Business Model B2B, B2D, B2C
Revenue Model Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Arbor Biotechnologies. To contact Arbor Biotechnologies, visit arbor.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Arbor Biotechnologies compare?

A PDF of Arbor Biotechnologies and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Arbor Biotechnologies soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 28, 2026

Arbor Biotechnologies participated in The ALS Association’s annual Walk to Defeat ALS in Boston.

Arbor Biotechnologies a competitor of yours? Have our desk watch it

About Arbor Biotechnologies

Arbor Biotechnologies, founded in 2016, is at the forefront of the Biopharma, Biotechnology, and Life Sciences industries. Based in the United States, this next-generation gene editing company aims to tackle genetic diseases with its slogan, "Genetic medicines for genetic diseases."

The company stands out with its extensive toolbox of proprietary genomic editors, enabling it to select the optimal solutions for each disease, effectively working backward from disease pathology. This innovative approach positions Arbor Bio as a pioneer in potentially curative genomic medicine development.

In its recent financing milestone, Arbor Biotechnologies secured a Late VC investment dated 01 October 2025, with Samsung Ventures as a key investor. This investment not only reinforces confidence in the company's strategic vision but also underlines its potential for significant impact in the realm of genetic therapies.

Business keywords: Genetic Medicines, Gene Editing, Genomic Editors, Disease Pathology, Diagnostic Development, Genome Sequencing, Gene Synthesis, High-Throughput Screening, Bio-Discovery, CRISPR, Bioengineering, Protein Discovery, Molecular Biology

Services & Products

Developing novel gene editing treatments
Providing a diversified editing toolbox
Pioneering next-generation gene therapies
Conducting clinical trials for genetic diseases

Target Customers

Patients living with genetic diseases Healthcare providers seeking genetic solutions Biotechnology investors and partners Scientific and medical researchers

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Late VC Undisclosed 1
Samsung Ventures
Samsung Ventures
01 Oct 2025
Series C $73.90M 15
Arch Venture Partners Partners Investment Qatar Investment Authority
Arch Venture Partners, Partners Investment +13
01 Mar 2025
Series B $215.00M 19
GreatPoint Ventures Arch Venture Partners Illumina Ventures
GreatPoint Ventures, Arch Venture Partners +17
01 Nov 2021
Early VC $15.60M -
01 Jun 2017
Spinout Undisclosed 3
Massachusetts Institute of Technology, Broad Institute +1
01 Jan 2016

Arbor Biotechnologies Alternatives & Competitors

View All Alternatives
Arbor Biotechnologies vs
Octant
Octant United States

Developing synthetic technology and applying next-generation DNA sequencing, gene synthesis, and gen...

Series B
69 employees
Biotechnology, Life Sciences
Compare Arbor Biotechnologies vs Octant
Arbor Biotechnologies vs
Affinia Therapeutics
Affinia Therapeutics United States

Building the next generation of gene therapies

Series C
30 employees
Biotechnology, Health Care
Compare Arbor Biotechnologies vs Affinia Therapeutics
Arbor Biotechnologies vs
Modalis Therapeutics
Modalis Therapeutics United States

Modalis is an emerging biotech company that develops therapeutics using CRISPR based technology

IPO
23 employees
Biotechnology, Health Care
Also compare with: Arbor Biotechnologies vs Alithea Genomics Alithea Genomics View all alternatives

FAQ About Arbor Biotechnologies

Genetic medicines for genetic diseases
Arbor Biotechnologies was founded in 2016.
Arbor Biotechnologies is headquartered in Cambridge, United States.
Arbor Biotechnologies operates in Biopharma, Biotechnology and Life Sciences. Its work centres on Genetic Medicines, Gene Editing, Genomic Editors and Disease Pathology. Its customers include Patients living with genetic diseases, Healthcare providers seeking genetic solutions and Biotechnology investors and partners.
Arbor Biotechnologies has a B2B, B2D and B2C business model. Its revenue comes from Licensing and Service Fee.
Arbor Biotechnologies has approximately 101 employees.
Arbor Biotechnologies has completed 5 funding rounds, raising a total of $304.50M.
Arbor Biotechnologies offers: Developing novel gene editing treatments, Providing a diversified editing toolbox, Pioneering next-generation gene therapies, Conducting clinical trials for genetic diseases.
Top alternatives and competitors to Arbor Biotechnologies include Octant, Affinia Therapeutics, Modalis Therapeutics, Prime Medicine, Inc., KSQ Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arbor Biotechnologies and Octant are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Arbor Biotechnologies, https://bouncewatch.com/company/arbor-biotechnologies, updated 5 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout